New inhaled treatment for respiratory viruses in adults and the elderly
Official title: SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV
Funded at Mucommune, LLC · NIH-10810719 · Data updated 2026-11-12
This study is testing a new inhaled treatment called MM004 that aims to help older adults and those with weakened immune systems fight off respiratory viruses like RSV and MPV, by delivering medicine directly to the lungs where it's needed most.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | March 4, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,037,049 |
| NIH project number | 5R44AI157661-03 |
| Project ID | NIH-10810719 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults and immunocompromised individuals who are at high risk for severe respiratory illness caused by RSV and MPV.
✕Less likely to help
Patients who are not at risk for RSV or MPV infections, such as healthy young adults, may not benefit from this research.
What this research studies
This research focuses on developing a bispecific inhaled immunotherapy called MM004 to treat respiratory syncytial virus (RSV) and metapneumovirus (MPV), which are significant causes of respiratory illness in older adults and immunocompromised individuals. The approach involves creating a topical monoclonal antibody that targets these viruses directly in the airways, potentially providing a more effective treatment option than current therapies. By utilizing a unique 'muco-trapping' mechanism, the treatment aims to enhance the delivery of the antiviral directly where it is needed most. Patients participating in this research may receive this innovative therapy as part of the clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for RSV and MPV, significantly reducing morbidity and mortality in affected patients.
How similar studies have gone: While there are currently no effective treatments for MPV, the approach of using bispecific monoclonal antibodies for respiratory viruses is novel and has not been extensively tested in this context.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Cone, Richard — Mucommune, LLC
- Study coordinator: Cone, Richard
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.